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Abstract. Aminoglycoside ototoxicity is common in clinical 
practice but reliable protective agents currently do not exist. 
Aminoglycoside regimens causing ototoxicity in different 
laboratory animals are under investigation. The assess-
ment method used most commonly to determine auditory 
effects is the auditory brainstem response (ABR). Distortion 
product otoacoustic emissions (DPOAE) have been used less 
frequently. A precise recommendation on the specific method 
to assess peripheral auditory function before and after amino-
glycoside toxicity in mice does not exist. In order to evaluate 
various mouse models for ototoxic injury caused by various 
aminoglycoside regimens, there is a need for performing 
preliminary tests in small cohorts before large experiments. 
The aim of our study was to investigate different aminoglyco-
side regimens that cause substantial ototoxic damage in vivo. 
Aminoglycosides are safe and produce a detectable hearing 
threshold shift in a small cohort of mice that can be used as 
a model for preliminary tests. Different ototoxic regimens 
were assessed by ABR and DPOAE measurements pre- and 
post‑treatment. Further, the sensory cell loss was quantified 
by counting hair cells in the cochlea. It was revealed that an 
ototoxic regimen with kanamycin twice daily for 15 consecu-
tive days is safe, well tolerated and produces an early significant 
hearing threshold shift detected by DPOAE in a small cohort 
of mice. The study compared ABR and DPOAE in mentioned 
regimens for the first time and illustrated that DPOAE is well 
suited for detecting hearing threshold shifts in high frequen-
cies before ABR threshold shifts occur in accordance with 
predominating outer hair cell damage mainly in the basal turn 
of the cochlea.
Introduction
Hearing impairment is one of the most relevant chronic 
disorders in humans worldwide with an increasing incidence 
in industrial countries. According to the WHO, 360 million 
people currently suffer from disabling hearing loss (1). 
Congenital deafness, aging, acoustic trauma or ototoxins (e.g., 
uremic, drug induced) are the most common causes of partial 
or total hearing loss. Hearing loss due to ototoxic drugs such as 
aminoglycosides or platinum-based chemotherapeutic agents 
can be either reversible and temporary or irreversible and 
permanent. The severity of the effect depends on several factors 
including the level of the dose, duration of treatment, genetic 
predisposition of the patient or animal and route of administra-
tion (2-4). The hearing loss is typically sensorineural, bilateral 
and progressive (5). Hearing loss is a major limiting factor in 
the clinical use of aminoglycosides and represents one of the 
main preventable causes of deafness (6-8). An otoprotective 
compound is yet to be found.
Early and accurate detection of cochlear damage 
during aminoglycoside administration is a major concern 
for health care professionals. The treatment of choice to 
prevent drug-induced ototoxicity is once-daily dosing and 
careful monitoring of serum drug concentrations as well as 
auditory testing. At present, finding otoprotective compounds 
is of vast interest. Cochlear hair cell damage in vitro by 
aminoglycosides such as Gentamicin and Kanamycin has been 
described in literature by several different research groups and 
is an established known phenomenon. In vivo experiments 
are performed to investigate drug-induced cochelotoxicity 
and tolerance while co-morbidities ought to be avoided. In 
order to research otoprotection in aminoglycoside-induced 
hearing impairment, a reliable model for preliminary tests 
performed in small cohorts needs to be established. Common 
experimental animals have included guinea pigs, rats and 
chinchillas. The larger rodents' pharmacokinetic profiles differ 
significantly from those of small rodents such as mice (9‑11). 
In the past, large rodents have been used not only because of 
their body size and easier breeding or surgical intervention 
but also because of the greater drug-induced toxicity of their 
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auditory system compared to mice (3,12,13). Nevertheless, 
mice are widely used and suitable as research models and 
can be genetically modified. Genetic standardization and 
relative ease of engineering make the mouse a preferred 
model for hearing research in vivo, especially when studied 
at a young age (up to 20 weeks) (5,12). Furthermore, the inner 
ear anatomy of mice is similar to that of humans (14). The 
mouse has served as a successful model in inner ear research, 
including auditory and vestibular disorders (15), inner ear 
development, noise-induced hearing loss and drug-induced 
ototoxicity (13,16-18). Yet, mouse models have shown high 
resistance to aminoglycoside-induced cochlear damage (13). 
Some researchers have combined aminoglycosides and loop 
diuretics to take advantage of their synergistic effect to 
increase the rate of cochlear injury (17,19-22).
To identify a mouse model for cochlear injury, different 
research groups (5,9,12,13,16-18,22,23) have investigated 
aminoglycoside ototoxicity in different strains of mice, which 
has yielded variable results for similar drug dose regimens. 
Also, similar dose regimens in identical mouse strains have 
produced dissimilar results. Kendall et al (24), have suggested 
the use of C57BL/6J strains in auditory research instead of 
C57BL/6N, as the latter have genetically drifted within 
their subpopulation and show irregular auditory thresholds 
among different populations. A robust in vivo mouse model 
for aminoglycoside-induced ototoxicity remains to be estab-
lished. The most commonly used method to assess functional 
auditory effects is the auditory brainstem response (ABR). 
Less frequently, distortion product otoacoustic emission 
(DPOAE) have been used. Wu et al (13), presented an adult 
mouse model for kanamycin ototoxicity using ABR only. We, 
however, assessed different dose regimens for gentamicin- and 
kanamycin-induced ototoxocity, that is capable of causing 
substantial cochlear damage in young mice while maintaining 
a low mortality rate and being able to detect cochlear damage 
in a small cohort, which can be used as a model for future 
preliminary cochelotoxic tests.
Materials and methods
Animals. Four- to 6-week-old C57BL/6J mice supplied by 
Charles River (Charles River, Freiburg im Breisgau, Germany) 
were used to assess the optimal aminoglycoside dose regi-
ment needed to induce ototoxic hair cell injury for purposes 
of research. Mice were divided and housed in cages (Type 2 
IVC; Allentown Inc., Allentown, PA, USA) in groups of four 
(M1-M4), with wood shaving litter (Lignocel select premium; 
J. Rettenmaier & Söhne GmbH, Rosenberg, Germany) under 
standard conditions: 12:12 h photoperiod, room temperature 
between 20 and 22˚C, relative humidity of 45‑55% and 20‑22 
air changes per hour. Standard mouse food (cat. no. 3436, 
Kliba Nafag Provimi Kliba AG, Kaiseraugst, Switzerland) 
and water were available ad libitum. All mice were allowed to 
acclimatize to the animal facility for at least one week before 
testing was begun. Health monitoring was performed follo-
wing FELASA recommendations (25). All animal procedures 
were carried out according to our approved animal research 
protocols (permission number 19/2011, Veterinary Department 
of Zurich, Kantonales Veterinäramt Zürich, Switzerland). Due 
to the previously described high mortality rates with systemic 
gentamicin administration (5), the local veterinary department 
(Kantonales Veterinäramt Zürich, Switzerland) permitted us 
to use a limited cohort of animals (n=16) for the experiments. 
Three groups received different aminoglycoside treatment 
protocols including gentamicin, kanamycin and kanamycin 
plus furosemide. The fourth group served as a control and 
received no treatment. Every mouse was checked daily during 
the experiment for weight and activity behavior.
Drug administration. The details of dosing and timing are listed 
in Table I and Fig. 1A. Mice from each experimental group 
were treated with the corresponding protocol. Kanamycin 
(Sigma Aldrich, Buchs, Switzerland) was dissolved in physi-
ological saline to obtain the desired concentration according 
to the instructions provided by the supplier. Each mouse from 
the gentamicin (Hexal, Holzkirchen, Germany) group received 
a once-daily dose by intraperitoneal (i.p.) drug administration 
at 8:00 a.m. for 7 days. Each mouse from the kanamycin group 
received twice daily subcutaneous (s.c.) drug administration at 
8:00 a.m. and 8:00 p.m. for 15 days. Kanamycin plus furose-
mide (Sanofi‑Aventis, Vernier, Switzerland) was administered 
as a single dose in which furosemide was infused into the 
tail vein within 5 min after kanamycin s.c. injection. The 
dosage administered was selected on the basis of previously 
published and weight-adapted ototoxic protocols using genta-
micin at 200 mg/kg body weight (BW) (12), kanamycin at 
800 mg/kg BW (5), kanamycin plus furosemide at 1,000 mg/kg 
BW plus 100 mg/kg BW (22). The injections were adjusted 
daily according to body weight and were administered using a 
1-ml syringe and 25-gauge needle in a standardized manner by 
the same person in the same setting, at the same time each day.
Measures of auditory function. The ABR and DPOAE 
measurements were performed on all animals before starting 
the treatment protocols, at 1-week and the two groups with kana-
mycin were also tested at 3 weeks post-treatment (Fig. 1A). The 
DPOAE were performed one day after ABR measurements, 
therefore in two separate anesthesias. Mice were anaesthetized 
by i.p. injection of a combination of ketamine (65 mg/kg body 
weight, Graeub, Switzerland), xylazine (13 mg/kg body weight, 
Bayer HealthCare, Leverkusen, Germany) and acepromazine 
(2 mg/kg body weight, Fatro S.p.A., Ozzano dell'Emilia, Italy). 
After loss of the withdrawal reflex, the animals were placed 
on a heating pad in a soundproof chamber. Photos showing the 
method for hearing assessment are provided as supplementary 
material (Fig. S1).
ABR testing. Hearing was evaluated by ABR as previously 
described (26). Needle electrodes were inserted subcutaneously 
at the vertex (active electrode), in the ipsilateral mastoid 
region (reference electrode) and in the lumbar region (ground 
electrode). Tone bursts of 4, 8, 12, 16, 24, 32 kHz were generated 
with SigGenRP software (Tucker-Davis Technologies TDT, 
Gainesville, FL, USA). The stimuli were delivered through 
a closed acoustic system and were calibrated using a sound 
level meter (Precision Integrating Sound Level Meter Type 
2218; Brüel & Kjaer, Naerum, Denmark) and an ear simulator 
(Type: 4157, Brüel & Kjaer, Naerum, Denmark). Sounds 
were delivered from a free‑field electrostatic speaker (ES1, 
TDT) placed into the ear canal. The ABR recordings were 
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obtained with a Tucker-Davis Technologies (TDT) System 
III workstation running BioSig RP. The tone-type sounds of 
5 ms duration were presented at a rate of 10 per second and 
reduced in level from 80 dB SPL to 5 dB SPL in 5-dB steps. 
The ABR waveforms were averaged in response to 300 tones. 
Hearing threshold was defined as the lowest level that induced 
the appearance of a visually detectable peak in the response 
waveform.
DPOAE testing. DPOAE at 2f1-f2 were obtained 24 h 
following ABR recordings from mice that were anesthesized 
as described above. We used the Real-time Signal Processing 
System III from Tucker-Davis Technologies and procedures 
described previously (27). The primary tones produced by 
two separate speakers (ES1, TDT) were placed as a combi-
nation microphone/speaker system in the animal's sealed ear 
canal near the tympanic membrane. The DPOAE recordings 
were made with a low-noise microphone ER 10B (Etymotic 
Research, Elk Grove Village, IL, USA). All stimuli were 
digitally synthesized at 200 kHz using TDT SigGen software. 
Primary tone frequencies (f1 and f2) differed by a factor of 
1.25 and were presented initially at 65- and 50-dB SPL respec-
tively. The test frequencies were at 4, 8, 16, 32 kHz and levels 
were reduced in 10-dB steps from 80 to 30 dB. A fast Fourier 
Transform (FFT) was performed to obtain the magnitude of 
the 2f1-f2 distortion product. A peak at 2f1-f2 in the spectrum 
was accepted as a DPOAE if it was 6 dB above the noise floor 
in the same frequency.
Figure 1. (A) Schematic diagram describing the experimental procedure and timeline of hearing assessment by ABR and DPOAE at 1 day pre-treatment, 1 and 
3 weeks post‑treatment, following sacrifice and histological studies. Treatment groups are listed by drug name. (B) Absolute and (C) relative weight in grams 
of mice during treatment period. ABR, auditory brainstem responses; DPOAE, distortion product otoacoustic emissions.
Table I. Treatment regimens and mortality rate. 
Drug/Group  Dose, rate, route  No. of deaths/No. of injected mice (mortality rate) (%)
Kanamycin  800 mg/kg/12 h, 15 days, s.c  0/4 (0)
Kanamycin + furosemide  1,000 mg/kg, s.c. + 100 mg/kg i.v.  0/4 (0)
Gentamicin  200 mg/kg/24 h, 7 days, i.p.  2/4 (50)
Dose per kilogram (kg) body weight. i.p., intraperitoneal; s.c., subcutaneous; i.v., intravenous.
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Hair cell count. Mice were transcardially perfused with 
freshly prepared 4% paraformaldehyde dissolved in PBS 
(pH 7.2) during anesthesia. The cochleae were removed and 
the round and oval windows were opened. The cochleae were 
postfixed for 48 h in the same fixative, decalcified for 96 h 
in RDF Mild Decalcifier (CellPath Ltd., Newtown Powys, 
Wales, UK) and embedded in paraffin. Serial sections (2 µm) 
were cut using a HM 355S Automatic Microtome (Thermo 
Fisher Scientific, Inc., Waltham, MA, USA). Sections were 
collected on SuperFrost Plus slides (Thermo Fisher Scientific, 
Inc.), dried on a heating plate at 37˚C overnight and stained 
with H&E. Observer-blinded inner hair cell (IHC) and outer 
hair cell (OHC) counts at each of the basal, middle and apical 
cochlear turn were performed on para-midmodiolar sections 
obtained from five non‑overlapping 20‑µm segments in 
each cochlea. For each segment, three consecutive sections 
were mounted and the best-preserved section was used 
for counting. The presence of a hair cell was assumed if a 
nucleus was clearly visible in the typical anatomical loca-
tion next to the tunnel of Corti. Additionally, hair cells were 
distinguished from other cells, e.g., supporting cells, by their 
denser and therefore darker stained nuclei. Images were 
acquired using an AxioCam ICc5 (Carl Zeiss Microscopy 
GmbH, Jena, Germany) on a Leica DM RB light microscope 
(Leica Camera AG, Wetzlar, Germany) and processed with 
Adobe Photoshop CS5 software (v.12.0, Adobe Systems, San 
Jose, CA, USA).
Statistical analysis. ABR, DPOAE and hair cell counts 
were analysed by two-way ANOVA with Dunnett's multiple 
comparison testing using Prism (v.6.0 for Apple Macintosh, 
GraphPad Software, San Diego, CA, USA). Data are presented 
as mean ± SEM. P<0.05 was considered to indicate a statisti-
cally significant difference.
Results
Systemic administration of kanamycin is a safe method to 
cause hearing damage in young mice. The administration 
of kanamycin in two different regimens (Table I) yielded a 
mortality rate of 0%. None of the animals appeared ill and no 
weight change >15% was observed during and after treatment 
(Fig. 1B and C). In contrast, systemic administration of previ-
ously reported ototoxic doses of aminoglycosides (5,12-22), has 
been associated with adverse effects. The gentamicin-group 
had the highest systemic toxicity with a mortality rate of 50%. 
One mouse was found dead within 24 h after the first injection 
and another mouse died within 24 h after the last injection on 
day 7.
Hearing assessment. Hearing impairment due to ototoxic 
effects was assessed by measuring frequency‑specific ABR 
and DPOAE threshold before and after antibiotic treat-
ment. After conferring with the veterinary department, the 
gentamicin group experiment was dismissed on Day 7 after 
occurrence of a 50% mortality rate. The control group was 
measured on day 0 and day 21. At baseline, average hearing 
threshold of all mice was 13 dB SPL (range +/- maximum 
15 dB) for the 16 kHz tone ABR, where mice are reported to 
hear most sensitively (28).
DPOAE recordings showed significant threshold shifts in the 
higher frequencies at early stage. The kanamycin regimen 
caused significant cochlear damage, which was detectable by 
DPOAE, showing threshold shifts in the higher frequencies 
(8, 16 and 32 kHz). Combined with furosemide as a single 
dose, a significant threshold shift was detected at 32 kHz. In the 
gentamicin group, DPOAE were not significantly altered post 
treatment (Fig. 2A-C). The control group had no significant 
changes in DPOAE threshold.
ABR recordings showed a tendency toward an increase of 
hearing thresholds. The overall threshold shift between pre- 
and post-treatment for the kanamycin only group (Fig. 2D) 
ranged from 12-18 dB (mean 14.3 dB). The kanamycin-furo-
semide group (Fig. 2E) had overall threshold shifts of 5-13 dB 
(mean 9.6 dB) between pre- and post-treatment. The genta-
micin group (Fig. 2F) as well as the control group showed 
no substantial threshold shifts. When focused on individual 
animal threshold measurements, the shifts showed a hetero-
genic variance between the mice and between the two ears 
of the same mouse (data not shown). No statistical significant 
threshold shifts were observed in any group by ABR, however 
ABR show a trend for hearing threshold elevation after 
kanamycin-induced ototoxicity.
Kanamycin treatment causes a significant hair cell loss in the 
organ of Corti. Histological evaluation of the cochleae revealed 
a considerably reduced amount of OHC per organ of Corti 
(OC) in the kanamycin-only group, especially in the basal turn, 
compared to the control group, where no OHC loss was observed 
(Fig. 3). No IHC loss was found in any group and no OHC loss 
was found in the gentamicin group. To quantify these changes, 
we performed IHC and OHC counts on sections of 3 animals 
per group (Fig. 4). OHC loss in the kanamycin group was 
predominant in the basal turn of the cochlea (1.4±0.2 OHC/OC 
vs. 3.0±0.1 OHC/OC, P<0.0001), less marked in the middle 
turn (2.3±0.2 OHC/OC vs. 2.9±0.1 OHC/OC, P<0.05) and 
only a slight hair cell loss was observed in the apical turn 
(2.6±0.16 OHC/OC vs. 3.1±0.1 OHC/OC, P<0.05). No signifi-
cant OHC loss was found in the kanamycin-furosemide and 
the gentamicin group, except in the apical turn, where the 
kanamycin‑furosemide produced a minor but significant OHC 
loss compared to the control group (2.6±0.16 OHC/OC vs. 
3.1±0.1 OHC/OC, P<0.05). No significant IHC loss was found 
in any treatment group compared to the control group.
Discussion
Hearing impairment caused by cochleotoxic agents is a 
prevalent clinical issue. Ongoing studies are trying to find 
protective agents against ototoxicity. The mouse has served as 
a consistent model to study the inner ear in vivo. So far, there 
have been no precise recommendations regarding ototoxic 
regimen in a mouse model, fulfilling requirements such as 
being simple to perform, safe and causing substantial inner 
ear damage. In order to evaluate various mouse models for 
ototoxic injury caused by various aminoglycoside regimens, 
preliminary tests in small cohorts need to be performed 
preceding large scaled experiments. The aim of our study was 
to investigate different aminoglycoside regimens that cause a 
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substantial ototoxic damage in vivo, which are simple, safe 
and produce a detectable hearing threshold shift already in 
a small cohort of mice. We show that an ototoxic regimen 
with kanamycin twice daily for 15 consecutive days is simple 
to employ, well tolerated and produces a significant early 
hearing threshold shift in a small cohort of mice. At the same 
time, the small cohort itself and the lack of saline injection 
of the control group is a limitation to our study. We demon-
strate a higher sensitivity of DPOAE, as thereby a hearing 
threshold shift is detectable earlier in high frequencies and 
correlates with the outer hair cell damage mainly in the basal 
turn of the cochlea. The known target of aminoglycoside 
ototoxicity are the hair cells of the organ of Corti, which are 
responsible for the mechano-sensory transduction of sound in 
the auditory system (29). These vulnerable hair cells are not 
capable of regeneration, and their damage leads to lifelong 
hearing impairment. ABR have been used to characterize the 
auditory system of various mouse strains and mutants. The 
DPOAE serve as a noninvasive tool to assess cochlear func-
tion, specifically that of the vulnerable OHCs. While ABR 
have been used as the main non-invasive method to assess 
auditory function in mouse models due to the simplicity 
and reliability of the method, DPOAE can provide a more 
direct means of assessing peripheral function by assessing 
OHC functional changes. Aminoglycosides have a narrow 
therapeutic range causing large spreads in hearing thresholds 
leading to high standard deviations. Mice have proven to have 
a high resistance to aminoglycoside-induced hair cell loss and 
to cochlear damage in general (18). Before appreciable altera-
tions in auditory function after aminoglycoside treatment was 
detected, our mouse cohorts required close to lethal doses 
for treatment, with the gentamicin group showing obvious 
systemic toxic effects. We chose to study the C57BL/6 strain 
because it is widely used as a transgenic modified mouse 
model and is therefore interesting as an in vivo animal model, 
especially to study aminoglycoside-induced ototoxicity. Age 
is also a factor, as young mice are more ideal as aminoglyco-
side ototoxicity models because they have a higher sensitivity 
to aminoglycosides than in adult life (12,13). Poirrier et al (9), 
hypothesized that genetic and environmental differences 
between mouse strains influence responses to various toxins 
including ototoxins. Researchers have been combining 
aminoglycosides and loop diuretics to study the loss of hair 
cells in rodents and describe a significant increase in hearing 
loss (16-18,23-30). The synergistic effects of a loop diuretic 
and an aminoglycoside occur because the aminoglycosides 
pass the blood-brain barrier allowing to spread effectively 
through the cochlea (31,32) combined with a decreased renal 
clearance (33). Because our kanamycin plus furosemide group 
received only a single dose and showed no significant hearing 
loss nor hair cell damage, we conclude that this dosage is 
insufficient in producing enough cochlear damage. In the 
Figure 2. DPOAE overall threshold (dB SPL) in mice at pre-treatment and post-treatment. (A) Kanamycin group, (B) Kanamycin + furosemide group and 
(C) Gentamicin group. Frequency‑specific ABR overall threshold (dB SPL) in mice at pre‑treatment and post‑treatment. (D) Kanamycin group, (E) Kanamycin 
+ furosemide group and (F) Gentamicin group. Significant threshold shifts are marked with an asterisk. Data are presented as the mean ± SEM. *P<0.05 vs. 
controls. DPOAE, distortion product otoacoustic emissions; ABR, auditory brainstem responses; dB SPL, decibel sound pressure level; s.c., subcutaneous; 
i.v., intravenous; i.p., intraperitoneal; kHz, kilohertz.
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inner ear, damage is first evident as a loss of OHCs at the 
base of the cochlea, spreading further towards the apex with 
continued drug treatment (7). Clinically, the ototoxic effect of 
aminoglycosides is characterized by a hearing loss initially 
in the high frequencies corresponding to hair cell damage in 
the lower basal turn (7,34). We also found early detection of 
hearing threshold shifts in the high frequencies with kana-
mycin only and with kanamycin plus furosemide in a small 
cohort. DPOAE were able to detect these threshold changes 
early. Tan et al (35) examined the effect of sub-damaging 
aminoglycoside doses on noise-induced hearing loss in 
guinea-pigs using DPOAE and ABR before and after treat-
ment. Aksoy et al (36,37) assessed hearing in rats before and 
after amikacin and trimetazidine or betahistin application. 
Moreover, Shi et al (38) were one of the first to demonstrate 
that DPOAE are preferable to ABR testing in the early detec-
tion of gentamicin toxicity of the cochlea in guinea pigs. They 
suggest that DPOAE provide earlier detection of cochlear 
damage caused by gentamicin than do ABRs. Kakigi et al (39) 
compared ABR, DPOAE and transiently evoked otoacoustic 
Figure 4. Counts of hair cells per OC examined for the apical, middle and basal turn of the cochlea. (A) IHC and (B) OHC counts for all groups. Results of the 
treatment groups were compared to those of the control group. Deata are expressed as the mean ± SEM. Error bars, absolute value of SEM. *P<0.05 vs. controls; 
**P<0.0001 vs. controls. Dunnett's test to adjust for multiple comparisons. IHC, inner hair cells; OHC, outer hair cells; OC, organ of corti.
Figure 3. Representative images of the organ of Corti from bright‑field microscopy of midmodiolar sections. (Aa‑Ac) Control group with full hair cell preserva-
tion. (Ba-Bc) Kanamycin group demonstrating OHC loss predominantly in the basal turn of the cochlea. (Ca-Cc) Kanamycin + furosemide group with full hair 
cell preservation. (Da‑Dc) Gentamicin group with full hair cell preservation. Ad‑Dd show basal turns in high magnification. White arrow head, IHC; black 
arrow head, OHC; scale bar, 50 µm. IHC, inner hair cells; OHC, outer hair cells; high mag., high magnification.
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emissions (TEOAE) in chinchillas treated with aminogly-
cosides. Their results suggest that DPOAE can be used to 
monitor hair cell function more accurately at specific anatom-
ical locations than can the other methods. Peguero et al (40) 
assessed hearing with both methods in different mouse strains 
(CBA/CaJ, 129S6/SvEvTac and 101/H). They determined that 
DPOAE detect early-onset OHC dysfunction despite normal 
ABR thresholds. It was evident in our study that DPOAE 
revealed hearing impairment early, while ABR still did not 
show any significant elevation of thresholds. Furthermore, we 
showed that Kanamycin alone for a prolonged application is 
able to cause damage in this small cohort of mice. A number 
of research groups have attempted to find an aminoglycoside 
inner ear damage regimen for rodents using different animals 
and strains, various drugs, doses and application methods. 
They have used primarily ABR for this purpose.
Three mouse groups living under identical conditions 
received different drug regimens to induce cochlear damage 
by systemic administration of high aminoglycoside doses. 
Significant threshold changes after kanamycin treatment 
were detected by DPOAE in the high frequencies (8, 32 and 
16 kHz). ABR was not able to detect significant threshold 
changes after 3 weeks. The kanamycin group had an overall 
shift of 12-19 dB SPL. The combination of kanamycin and 
furosemide lead to threshold shifts at 32 kHz. None of the 
kanamycin-treated groups had any deaths during or after the 
experiments. Histological examination and hair cell counts 
particularly showed a marked hair cell loss in the basal turn 
of the cochlea in mice treated with kanamycin, which in 
accordance with the functional measurements. The DPOAE 
measures detected hearing impairment primarily in the high 
frequencies, corresponding to the basal cochlear hair cells, 
defining OHC damage. While ABRs reflect the summed 
activity of the peripheral neuronal auditory system, DPOAEs 
are generated presynaptically and depend only on the integ-
rity of the OHC. Gentamicin at 200 mg/kg/24 h caused no 
significant threshold shift in DPOAE and ABR and was 
unsafe causing a high mortality rate. ABR showed a tendency 
towards hearing threshold shifts. While DPOAE are able to 
detect cochlear damage in a small cohort already, we postulate 
that a larger cohort is needed to show significant changes with 
ABR. Therefore, DPOAE can be used in preliminary experi-
ments finding cochlear damage in early stage and Kanamycin 
is a preferred method for cochlear damage in mice.
In summary, the present study compares for the first time 
DPOAE and ABR with aforementioned aminoglycoside 
regimens and demonstrates that Kanamycin treatment is a 
simple, reliable and safe regimen to induce damage to auditory 
function. Despite a small cohort and high-dosed administra-
tion period, the mortality rate was 0%. Significant hearing 
threshold changes were produced by the kanamycin regimen 
in a small cohort of mice and detected by DPOAE in early 
stage. DPOAE can therefore be used for early detection of 
outer hair cell damage induced by Kanamycin 800 mg s.c. 
2x/day for 15 days.
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